[Skip to Navigation]
Sign In
Medical News in Brief
May 24, 2023

Nonhormone Treatment for Menopausal Hot Flashes Receives FDA Approval

JAMA. 2023;329(22):1907. doi:10.1001/jama.2023.9151

The nonhormonal drug fezolinetant is the first of its kind to be approved by the US Food and Drug Administration (FDA) to treat moderate to severe hot flashes—periods of sweating, flushing, and chills—associated with menopause, the agency announced in a statement. Fezolinetant, marketed as Veozah, targets the neurokinin 3 receptor to restore the brain’s regulation of body temperature.

Add or change institution